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Abstract: Atripla® (Gilead Sciences Inc, Foster City, CA, USA and Bristol-Myers Squibb, New 
York City, NY, USA) is a coformulated single pill composed of efavirenz, emtricitabine, and 
tenofovir disoproxil, intended as a once-daily potent combination antiretroviral therapeutic agent. 
Its efficacy is equivalent to the 3 component drugs taken in a combination as single medica-
tions. The coformulated antiretroviral regimen can be quite effective in patients whose human 
immunodeficiency virus is sensitive to all 3 components of Atripla. However, women at risk of 
pregnancy, already pregnant, or nursing mothers should not take Atripla, due to the teratogenic 
potential of the efavirenz moiety. Adverse effects are similar to those seen with the constituent 
medications, including potential central nervous system effects and renal toxicity. Since its US 
Food and Drug administration approval, prescriptions for Atripla have increased steadily.
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Introduction
Since the advent of highly active antiretroviral therapy (now referred to as 
  combination antiretroviral therapy [CART]), high levels of adherence are   requisite 
to achieve   maximal viral control and to improve immunologic status, which 
results in fewer acquired immunodeficiency syndrome defining events and lower 
mortality.1,2 Adherence with greater than 90% of prescribed doses has been indi-
cated to prevent   development of resistance and to achieve maximal viral control. 
Such high levels of adherence require tremendous compliance to what have often 
been complicated medical regimens with many potential adverse effects.1–3 Many 
factors contribute to the likelihood of greater CART adherence, including patient’s 
belief in the   efficacy of the regimen, lower pill burden, fewer or more manageable 
adverse effects, and less frequent dosing.4,5 Even going from twice-daily to   once-
daily regimens   significantly improves adherence.6 Thus, the ongoing goals of CART 
regimen development have been lesser pill burden, fewer dosages during the day, 
and fewer adverse effects.4,7
Development of Atripla
The earlier CART regimens required multiple pills with multiple dosages   during 
the day.8 These regimens usually consisted of more than 1 nucleoside reverse 
  transcriptase inhibitor (NRTI) and a protease inhibitor (PI). By the late 1990s, the 
potent once-daily nonnucleoside reverse transcriptase inhibitor (NNRTI), efavirenz, 
was developed (200-mg tablet with therapeutic dose of 600 mg) and was used in 
  combination with dual NRTI therapy then currently available, leading to twice-daily HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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regimens with potentially no more than 5–6 pills/day. With 
the subsequent formulation of a 600-mg pill of efavirenz, 
the pill burden was then reduced by 2 pills.9 Many human 
immunodeficiency virus (HIV)   clinical experts also desired 
PI-sparing regimens, believing that the non-PI regimens 
have fewer adverse effects.10,11 Tenofovir disoproxil fumar-
ate (marketed as Viread®; Gilead Sciences Inc, Foster City, 
CA, USA) received United States Food and Drug Admin-
istration (US FDA) approval as a   single 300-mg nucleotide 
reverse transcriptase inhibitor (NtRTI) pill taken once daily 
in October 2001.12,13 The   antiretroviral medication soon 
became commercially available in combination with 200-mg 
emtricitabine (another NRTI) as single pill once-daily Tru-
vada® (Gilead Sciences Inc, Foster City, CA, USA), further 
reducing pill burden and dosages during the day if combined 
with other once-daily medications.
Truvada plus efavirenz became a widely prescribed 2 pills 
once-daily regimen, especially among antiretroviral naive 
patients. All 3 medications were then coformulated into a 
single once-daily tablet called Atripla® (Gilead Sciences Inc, 
Foster City, CA, USA and Bristol-Myers Squibb, New York 
City, NY, USA) which was US FDA approved in July 2006, 
achieving the therapeutic goal of a single pill once-daily 
regimen.14 Of note, the coformulation required collabora-
tion between 2 pharmaceutical corporations (Bristol-Myers 
Squibb and Gilead Sciences Inc), a novel development for 
the HIV pharmaceutical industry.
Pharmacokinetics
Atripla is available for oral administration and was found 
to be bioequivalent to the combination of the single drug 
preparations in an open-label crossover study of 48 healthy 
subjects.15 As a coformulated product, Cmax values with food, 
relative to the fasting state, were reduced for emtricitabine 
(29%), increased modestly (14%) for tenofovir, and increased 
greatly (39%–79%) for efavirenz with increased area under 
the curve (AUC) values for both tenofovir and efavirenz.14 The 
AUC values are relatively similar to the single drug levels for 
the individual medications when administered in combination. 
Due to the Cmax values with food, efavirenz is advised to be 
taken on an empty stomach (usually at   bedtime), and the same 
recommendation applies to Atripla, in order to increase blood 
levels for emtricitabine and reduced for efavirenz.
Pharmacodynamics and efficacy
The mechanism of action of tenofovir and emtricitabine is based 
on the intracellular conversion of these drugs to their active 
metabolites, which then competitively inhibit HIV reverse 
transcriptase activity and viral replication.16,17 The mechanism 
of action of efavirenz is through   noncompetitive inhibition 
of the HIV reverse transcriptase.16
Atripla is highly efficacious when appropriately pre-
scribed.18,19 In the initial noninferiority clinical studies of 
the Atripla coformulation, not only was noninferiority dem-
onstrated compared to the twice-daily efavirenz–Combivir® 
(zidovudine plus lamivudine as fixed drug combination; 
GlaxoSmithKline plc, Middlesex, England), but also   superior 
efficacy was observed (71% HIV RNA , 400/mL with 
Atripla equivalent vs 58% with zidovudine-based regimen; 
P = 0.004).18 Fewer adverse effects also were reported, as 
well as improved adherence, compared with the Combivir-
based regimen.18,19 The improved adherence to a single pill 
regimen is not surprising, given the earlier studies of CART 
adherence. In fact, the authors reported improved adherence 
and efficacy comparing Truvada–efavirenz with tenofovir 
plus lamivudine plus efavirenz (2 pills compared with 
3 pills once daily).20 A systematic overview of efavirenz-
based clinical trials found that Atripla (or tenofovir plus 
lamivudine with efavirenz) had greater virologic response 
and fewer discontinuations than that of other NRTI/NtRTI 
combinations with efavirenz.21
The CD4 cell count response for Atripla is similar to that 
of its constituent medications. However, initial studies indi-
cated a better CD4 cell response with Atripla than Combivir 
plus efavirenz (190/µL vs 158/µL; P = 0.002).19 Other studies 
did not demonstrate a significant difference in CD4 changes 
between NRTI combinations together with efavirenz.22
Considerations with prescribing 
Atripla
As with any other CART regimen, a resistance test should 
be performed prior to regimen initiation.23,24 To prevent the 
development of resistance, the patient’s HIV virus should 
show susceptibility to all 3 components of the medication. 
The most common resistance mutations which would lead to 
decreased efficacy of Atripla are M184V/I (leading to emtric-
itabine resistance), K103N (efavirenz resistance), and K65R 
(tenofovir resistance).23,25 If any of these major mutations 
are present, Atripla should not be prescribed. The frequency 
of these mutations among antiretroviral naive patients vary 
based upon geographic location, but can be as high as over 
17%.26 In the initial study of Atripla, the K103N was the 
most common resistance mutation which developed with 
its use,19 followed by the M184V mutation, but few patients 
developed the K65R mutation.16,19 These mutations likely 
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patients, as they are not unique to Atripla and can develop 
prior to Atripla use.27
Reverse transcriptase mutations are the most com-
mon mutations among antiretroviral-experienced patients; 
M184V/I and K103N are the 2 most common mutations, 
given the frequent previous use of lamivudine (very similar in 
structure and virologic behavior to emtricitabine) and NNRTI 
medications that share the K103N mutation leading to class 
resistance.28 However, these are not the only mutations that 
can lead to Atripla resistance and all resistance testing should 
be interpreted by a clinician well versed in HIV resistance 
mutations.23 Further, these resistance mutations also often 
preclude simplification of a PI-containing or more complex 
regimen in a virologic-controlled patient because these muta-
tions may be “archived” by the virus and become manifest 
during incomplete antiretroviral therapy.
Resistance mutations are not the only prescribing con-
sideration for Atripla. Tenofovir can be associated with 
decreased renal function, and patients with impaired renal 
function, including older patients with seemingly normal 
creatinine values or patients with early HIV-associated 
nephropathy, often require dose adjustment of tenofovir 
and emtricitabine or preclude the use of tenofovir.29,30 In 
these situations, the fixed milligram dosing of Atripla pre-
cludes its use. Further, efavirenz has been associated with 
its own adverse effects. If a patient has had a severe rash or 
Stevens-Johnson syndrome with another NNRTI, efavirenz 
should be avoided.31 Because of potential for neuropsychi-
atric side effects with efavirenz, there is still debate about 
the use of efavirenz among patients with severe psychiatric 
disorders.32,33
Another prescribing consideration for Atripla is pregnancy 
or the risk of pregnancy. Efavirenz is potentially teratogenic 
and should not be used in women of reproductive age who are 
not using effective contraception, nor during pregnancy as 
it is deemed US FDA class C.34 The contraindication also 
applies to breast-feeding mothers.16 Although tenofovir has 
not been completely studied for its use in pregnancy, it is not 
generally considered to be contraindicated during pregnancy. 
It should be noted that Atripla is formulated at adult dosages; 
it is not intended for pediatric patients.35
There is a unique patient profile for which Atripla may be ide-
ally suited. HIV-infected patients with   hepatitis B virus (HBV) 
coinfection likely benefit from the tenofovir–emtricitabine 
components of Atripla.36 Both   tenofovir and emtricitabine 
have potent activity against hepatitis B. Patients with 
HIV/HBV coinfection have greater all-cause mortality and 
more aggressive liver disease.37 Therefore, they ideally should 
have viral suppression of both viruses.37 As with HIV disease, 
  monotherapy (especially with lamivudine or emtricitabine) can 
lead to HBV resistance and disease progression.38,39 Truvada, 
whether as part of Atripla or prescribed as part of a different 
CART regimen, allows potent combination therapy against 
hepatitis B as well as serving as the dual NRTI agent for HIV 
treatment. However, efavirenz should be used with caution 
in patients with severe liver disease, and tenofovir has been 
associated with lactic acidosis and steatosis.16 As adefovir 
(approved in the United States at low doses for hepatitis B 
treatment) and tenofovir are similar medications, they should 
not be administered concurrently.16
Adverse effects
In general, Atripla is well tolerated. The initial   considerations 
of the adverse effects of Atripla relate to the constituent 
  components of the medication. The adverse effects of 
  efavirenz are likely to occur sooner than other adverse 
effects. Acute (within 6 weeks of efavirenz initiation) adverse 
effects are usually central nervous system related, such as 
sleep disturbance, neuropsychological complaints, such as 
poor concentration or mood change, or rash.33,40,41 The rash 
is usually a typical appearing drug-related generalized 
  erythematous maculopapular rash. However, progression to 
Stevens-Johnson syndrome has been reported and severe rash 
requires discontinuation of the medication.31,33 Often, though, 
the rash responds to steroid treatment if started soon after 
onset and may not require medication discontinuation.
The sleep disturbances can be profound and can limit 
the use.33 However, the disturbances are thought to be 
self-limiting and most patients become used to the intense 
dreams. It should be noted that these central nervous system 
disturbances can occur even later in the course of treatment, 
and have been associated with poorer adherence and viral 
rebound.42 Although the neuropsychiatric effects of efavirenz 
can persist even through 2 years of therapy, studies have 
found them to be typically mild and tolerable.43 Long-term 
adverse metabolic effects, however, are not generally seen 
with efavirenz except hypertriglyceridemia (albeit less than 
with PI-containing regimens),44 but this effect can require 
treatment.45
The adverse effects of tenofovir are generally related to the 
renal effects of the medication. The renal adverse effects can 
be both acute and long term. Tenofovir has been associated 
with renal failure (43.3/100,000 person-years in expanded 
access and postmarketing safety databases) and renal tubular 
dysfunction (22.4/100,000 patient-years).46–48 Several case 
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dysfunction in patients taking tenofovir.49–55 The Swiss Cohort 
Study originally found tenofovir associated with renal func-
tion decline,56 although other studies have not found increased 
incidence of renal dysfunction with tenofovir compared with 
other NRTIs19,46,57–59 or felt the effect to be limited.59–63 Kaiser 
Permanente’s retrospective analysis64 (tenofovir-containing 
regimen [964 patients] or tenofovir-sparing regimens [683 
patients]) found that tenofovir-exposed patients had a larger 
relative decline in glomerular filtration rate (GFR) through 
104 weeks (−7.6 mL/min/1.73 m2 relative to tenofovir-sparing 
regimens; P , 0.001); the degree of the difference varied by 
baseline GFR, with the greatest effect seen in those patients 
with GFR . 80 mL/min/1.73 m2. Also from the Kaiser Per-
manente study, tenofovir-exposed patients had more frequent 
development of proximal tubular dysfunction over time (at 
52 weeks: hazard ratio [HR]adjusted = 1.95, P = 0.01 and at 
104 weeks: HRadjusted = 5.23, P = 0.0004), and had greater 
risk of medication discontinuation (HRadjusted = 1.21, P = 0.02) 
especially as renal function worsened, as compared with other 
NRTI combinations. Due to renal dysfunction, some patients 
may require tenofovir dose adjustment; if so, Atripla needs to 
be replaced with its individual components with appropriate 
dose reduction based on creatinine clearance. It should be 
noted that although studies have found that the decrease in 
renal function is greater if tenofovir is administered with PI, 
there is still significant reduction with efavirenz.55,64
Tenofovir is further associated with Fanconi Syndrome, 
a proximal renal tubular disorder characterized by leakage 
of protein, glucose, amino acids, phosphate, and bicarbon-
ate in the urine.65 Profound hypophosphatemia requiring 
phosphate repletion or medication discontinuation has been 
described. In addition, bone density loss and osteomalacia 
with teofovir use have been described, but the exact incidence 
is debated.16,66
The incidence of these adverse effects has not been 
reported to increase with coformulation of these constituent 
medications compared with the medications administered 
singly. However, longer term monitoring of the adverse 
effects of these medications (especially renal and bone 
complications) may demonstrate different incidences by 
formulation.
Use of Atripla in the United States
Atripla has found widespread use among antiretroviral naive 
patients. It is a recommended regimen for antiretroviral naive 
patients commencing antiretroviral therapy in many HIV 
treatment guidelines, including US Department of Health and 
Human Services expert panel guidelines.23 Its convenience 
and generally good tolerability make it a popular choice for 
both clinicians and patients. In a recent review of antiretro-
viral use in the Swiss Cohort, Atripla was the most frequent 
regimen used (28%).40
Even prior to the availability of Atripla, efavirenz and 
tenofovir had increasing prescriptions and market share.67 
Since its arrival in the United States market, Atripla has 
steadily become the initial regimen of choice for antiretroviral 
naive patients initiating CART. Over 30% of all HIV-infected 
patients on antiretroviral therapy in the United States use 
Atripla (personal communication). Pharmaceutical sales 
experts predict that Atripla will have the highest antiretro-
viral sales by 2013, even as other presently available single 
agents decline in sales.68 Kaiser Permanente can serve as an 
example. Since 2006, Kaiser Permanente, an integrated US 
health care system and the largest civilian integrated provider 
of HIV care in the United States, has dispensed over 56,000 
Atripla prescriptions, and this represents nearly 7% of all 
antiretroviral prescriptions in Kaiser Permanente during that 
time period. In 2009, 11% of all antiretroviral prescriptions 
filled in Kaiser Permanente were for Atripla, representing 
over 4,500 patients. Atripla was priced in the United States 
to be the equivalent price as the total cost of the 3 component 
medications.
As previously noted, its use in the United States for 
antiretroviral-experienced patients is more limited. Some 
switch studies from more complex or PI-based regimens 
to Atripla have shown continued viral control and success, 
but these studies have been among patients on their first 
antiretroviral regimen with likely prior susceptibility to 
the 3 antiretroviral medications in Atripla.69 Further, many 
patients can be safely changed from other NRTI combina-
tions plus efavirenz to Truvada plus efavirenz (or Atripla).18 
Also, many patients who were treated with the components of 
Atripla can be changed to the single pill once-daily safely.
Conclusion
Atripla is a potent and effective single pill once-daily 
  antiretroviral regimen that works well in patients whose virus is 
susceptible to the 3 constituent medications. However, further 
drug development and coformulations of other antiretroviral 
medications, particularly with a once-daily administration, are 
needed because some patients cannot tolerate or are resistant 
to Atripla. Given also that Atripla cannot be utilized during 
pregnancy or breastfeeding, alternative coformulations should 
be developed. In addition, monitoring for long-term effects is 
still needed for Atripla, a consideration for its use in resource 
limited setting. As always, further investigation is needed.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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